{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T17:21:18Z","timestamp":1794504078805,"version":"4.9.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T00:00:00Z","timestamp":1656028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T00:00:00Z","timestamp":1656028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>CX-5461 is a G-quadruplex stabilizer that exhibits synthetic lethality in homologous recombination-deficient models. In this multicentre phase I trial in patients with solid tumors, 40 patients are treated across 10 dose levels (50\u2013650\u2009mg\/m<jats:sup>2<\/jats:sup>) to determine the recommended phase II dose (primary outcome), and evaluate safety, tolerability, pharmacokinetics (secondary outcomes). Defective homologous recombination is explored as a predictive biomarker of response. CX-5461 is generally well tolerated, with a recommended phase II dose of 475\u2009mg\/m<jats:sup>2<\/jats:sup> days 1, 8 and 15 every 4 weeks, and dose limiting phototoxicity. Responses are observed in 14% of patients, primarily in patients with defective homologous recombination. Reversion mutations in PALB2 and BRCA2 are detected on progression following initial response in germline carriers, confirming the underlying synthetic lethal mechanism. In vitro characterization of UV sensitization shows this toxicity is related to the CX-5461 chemotype, independent of G-quadruplex synthetic lethality. These results establish clinical proof-of-concept for this G-quadruplex stabilizer. Clinicaltrials.gov NCT02719977.<\/jats:p>","DOI":"10.1038\/s41467-022-31199-2","type":"journal-article","created":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T05:02:59Z","timestamp":1656046979000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":166,"title":["Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies"],"prefix":"10.1038","volume":"13","author":[{"given":"John","family":"Hilton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Gelmon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6771-2999","authenticated-orcid":false,"given":"Philippe L.","family":"Bedard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongsheng","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna V.","family":"Tinker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Goodwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott A.","family":"Laurie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Jonker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron R.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary W.","family":"Veitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Renouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Hagerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbo","family":"Lui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6139-0696","authenticated-orcid":false,"given":"Bingshu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deb","family":"Kellar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takako","family":"Kono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9258-8184","authenticated-orcid":false,"given":"Brian Y. C.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5370-4592","authenticated-orcid":false,"given":"Damian","family":"Yap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9203-6323","authenticated-orcid":false,"given":"Daniel","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6819-7071","authenticated-orcid":false,"given":"Sean","family":"Beatty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Soong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen I.","family":"Pritchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Soria-Bretones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harriet","family":"Feilotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moira","family":"Rushton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8081-0799","authenticated-orcid":false,"given":"Lesley","family":"Seymour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0487-9599","authenticated-orcid":false,"given":"Samuel","family":"Aparicio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1080-0998","authenticated-orcid":false,"given":"David W.","family":"Cescon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,24]]},"reference":[{"key":"31199_CR1","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/s12033-011-9395-5","volume":"49","author":"TM Bryan","year":"2011","unstructured":"Bryan, T. M. & Baumann, P. G-Quadruplexes: from guanine gels to chemotherapeutics [Internet]. Mol. Biotechnol. 49, 198\u2013208 (2011).","journal-title":"Mol. Biotechnol."},{"key":"31199_CR2","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1039\/C3CC48616H","volume":"50","author":"SA Ohnmacht","year":"2014","unstructured":"Ohnmacht, S. A. et al. Discovery of new G-quadruplex binding chemotypes. Chem. Commun. 50, 960\u2013963 (2014).","journal-title":"Chem. Commun."},{"key":"31199_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14432","volume":"8","author":"H Xu","year":"2017","unstructured":"Xu, H. et al. CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1\/2 deficient tumours. Nat. Commun. 8, 14432 (2017).","journal-title":"Nat. Commun."},{"key":"31199_CR4","doi-asserted-by":"publisher","first-page":"4782","DOI":"10.1016\/j.jmb.2013.09.026","volume":"425","author":"M Tarsounas","year":"2013","unstructured":"Tarsounas, M. & Tijsterman, M. Genomes and G-quadruplexes: for better or for worse. J. Mol. Biol. 425, 4782\u20134789 (2013).","journal-title":"J. Mol. Biol."},{"key":"31199_CR5","doi-asserted-by":"publisher","first-page":"4033","DOI":"10.1038\/emboj.2011.316","volume":"30","author":"J Lopes","year":"2011","unstructured":"Lopes, J. et al. G-quadruplex-induced instability during leading-strand replication: G-quadruplex-induced instability. EMBO J. 30, 4033\u20134046 (2011).","journal-title":"EMBO J."},{"key":"31199_CR6","doi-asserted-by":"publisher","first-page":"5987","DOI":"10.1021\/acs.jmedchem.5b01835","volume":"59","author":"S Neidle","year":"2016","unstructured":"Neidle, S. Quadruplex nucleic acids as novel therapeutic targets. J. Med Chem. 59, 5987\u20136011 (2016).","journal-title":"J. Med Chem."},{"key":"31199_CR7","doi-asserted-by":"publisher","first-page":"9640","DOI":"10.1021\/ja404868t","volume":"135","author":"KIE McLuckie","year":"2013","unstructured":"McLuckie, K. I. E. et al. G-quadruplex DNA as a molecular target for induced synthetic lethality in cancer cells. J. Am. Chem. Soc. 135, 9640\u20139643 (2013).","journal-title":"J. Am. Chem. Soc."},{"key":"31199_CR8","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.critrevonc.2018.10.012","volume":"133","author":"E Chartron","year":"2019","unstructured":"Chartron, E., Theillet, C., Guiu, S. & Jacot, W. Targeting homologous repair deficiency in breast and ovarian cancers: biological pathways, preclinical and clinical data. Crit. Rev. Oncol. Hematol. 133, 58\u201373 (2019).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"31199_CR9","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1200\/JCO.2014.59.3178","volume":"33","author":"SM Domchek","year":"2015","unstructured":"Domchek, S. M. Evolution of genetic testing for inherited susceptibility to breast cancer. J. Clin. Oncol. 33, 295\u2013296 (2015).","journal-title":"J. Clin. Oncol."},{"key":"31199_CR10","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1200\/EDBK_238473","volume":"39","author":"TA Yap","year":"2019","unstructured":"Yap, T. A., Plummer, R., Azad, N. S. & Helleday, T. The DNA damaging revolution: PARP inhibitors and beyond. Am. Soc. Clin. Oncol. Educ. Book 39, 185\u2013195 (2019).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"31199_CR11","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/s41591-018-0009-7","volume":"24","author":"A Tutt","year":"2018","unstructured":"Tutt, A. et al. Carboplatin in BRCA1\/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat. Med. 24, 628\u2013637 (2018).","journal-title":"Nat. Med."},{"key":"31199_CR12","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.drudis.2013.08.012","volume":"19","author":"D Drygin","year":"2014","unstructured":"Drygin, D., O\u2019Brien, S. E., Hannan, R. D., McArthur, G. A. & Von Hoff, D. D. Targeting the nucleolus for cancer-specific activation of p53. Drug Discov. Today 19, 259\u2013265 (2014).","journal-title":"Drug Discov. Today"},{"key":"31199_CR13","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1158\/2159-8290.CD-18-1455","volume":"9","author":"A Khot","year":"2019","unstructured":"Khot, A. et al. First-in-hman RNA polymerase I transcription inhibitor CX-5461 in patients with advanced hematologic cancers: results of a phase i dose-escalation study. Cancer Discov. 9, 1036\u20131049 (2019).","journal-title":"Cancer Discov."},{"key":"31199_CR14","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1038\/nature06548","volume":"451","author":"SL Edwards","year":"2008","unstructured":"Edwards, S. L. et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451, 1111\u20131115 (2008).","journal-title":"Nature"},{"key":"31199_CR15","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1111\/j.1751-1097.2011.00978.x","volume":"87","author":"G de Guidi","year":"2011","unstructured":"de Guidi, G., Bracchitta, G. & Catalfo, A. Photosensitization reactions of fluoroquinolones and their biological consequences. Photochem. Photobiol. 87, 1214\u20131229 (2011).","journal-title":"Photochem. Photobiol."},{"key":"31199_CR16","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/s41586-019-1382-1","volume":"571","author":"P Jonsson","year":"2019","unstructured":"Jonsson, P. et al. Tumour lineage shapes BRCA-mediated phenotypes [Internet]. Nature 571, 576\u2013579 (2019).","journal-title":"Nature"},{"key":"31199_CR17","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1158\/1078-0432.CCR-13-0225","volume":"20","author":"P Bouwman","year":"2014","unstructured":"Bouwman, P. & Jonkers, J. Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors? Clin. Cancer Res. 20, 540\u2013547 (2014).","journal-title":"Clin. Cancer Res."},{"key":"31199_CR18","doi-asserted-by":"crossref","unstructured":"Masud T. et al. Ubiquitin-mediated DNA damage response is synthetic lethal with G-quadruplex stabilizer CX-5461. Sci. Rep. 11, 9812 (2021).","DOI":"10.1038\/s41598-021-88988-w"},{"key":"31199_CR19","doi-asserted-by":"publisher","first-page":"e65184","DOI":"10.7554\/eLife.65184","volume":"10","author":"M Bossaert","year":"2021","unstructured":"Bossaert, M. et al. Transcription-associated topoisomerase 2\u03b1 (TOP2A) activity is a major effector of cytotoxicity induced by G-quadruplex ligands. Elife 10, e65184 (2021).","journal-title":"Elife"},{"key":"31199_CR20","doi-asserted-by":"publisher","first-page":"6468","DOI":"10.1038\/s41467-021-26640-x","volume":"12","author":"M Pan","year":"2021","unstructured":"Pan, M. et al. The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma. Nat Commun 12, 6468 (2021).","journal-title":"Nat Commun"},{"key":"31199_CR21","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.cell.2020.05.040","volume":"182","author":"M Olivieri","year":"2020","unstructured":"Olivieri, M. et al. A genetic map of the response to DNA damage in human cells. Cell 182, 481\u201396.e21 (2020).","journal-title":"Cell"},{"key":"31199_CR22","doi-asserted-by":"publisher","first-page":"4053","DOI":"10.1073\/pnas.1921649117","volume":"117","author":"PM Bruno","year":"2020","unstructured":"Bruno, P. M. et al. The primary mechanism of cytotoxicity of the chemotherapeutic agent CX-5461 is topoisomerase II poisoning. Proc. Natl. Acad. Sci. USA 117, 4053\u20134060 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"31199_CR23","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/S1359-6349(09)70018-7","volume":"7","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. & Verweij, J. 11 New response evaluation criteria in solid tumors: RECIST GUIDELINE VERSION 1.1 [Internet]. Eur. J. Cancer Suppl. 7, 5 (2009).","journal-title":"Eur. J. Cancer Suppl."},{"key":"31199_CR24","doi-asserted-by":"publisher","first-page":"e0178706","DOI":"10.1371\/journal.pone.0178706","volume":"12","author":"S Haile","year":"2017","unstructured":"Haile, S. et al. Automated high throughput nucleic acid purification from formalin-fixed paraffin-embedded tissue samples for next generation sequence analysis. PLoS ONE 12, e0178706 (2017).","journal-title":"PLoS ONE"},{"key":"31199_CR25","unstructured":"Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM [Internet]. arXiv Available from: http:\/\/arxiv.org\/abs\/1303.3997 (2013)."},{"key":"31199_CR26","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41592-018-0051-x","volume":"15","author":"S Kim","year":"2018","unstructured":"Kim, S. et al. Strelka2: fast and accurate calling of germline and somatic variants. Nat. Methods 15, 591\u2013594 (2018).","journal-title":"Nat. Methods"},{"key":"31199_CR27","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/bioinformatics\/btr629","volume":"28","author":"J Ding","year":"2011","unstructured":"Ding, J. et al. Feature-based classifiers for somatic mutation detection in tumour\u2013normal paired sequencing data. Bioinformatics 28, 167\u2013175 (2011).","journal-title":"Bioinformatics"},{"key":"31199_CR28","doi-asserted-by":"publisher","first-page":"D766","DOI":"10.1093\/nar\/gky955","volume":"47","author":"A Frankish","year":"2019","unstructured":"Frankish, A. et al. GENCODE reference annotation for the human and mouse genomes [Internet]. Nucleic Acids Res. 47, D766\u2013D773 (2019).","journal-title":"Nucleic Acids Res."},{"key":"31199_CR29","doi-asserted-by":"publisher","first-page":"D1062","DOI":"10.1093\/nar\/gkx1153","volume":"46","author":"MJ Landrum","year":"2018","unstructured":"Landrum, M. J. et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res 46, D1062\u2013D1067 (2018).","journal-title":"Nucleic Acids Res"},{"key":"31199_CR30","doi-asserted-by":"publisher","first-page":"D941","DOI":"10.1093\/nar\/gky1015","volume":"47","author":"JG Tate","year":"2019","unstructured":"Tate, J. G. et al. COSMIC: the catalogue of somatic mutations in cancer [Internet]. Nucleic Acids Res. 47, D941\u2013D947 (2019).","journal-title":"Nucleic Acids Res."},{"key":"31199_CR31","doi-asserted-by":"publisher","first-page":"80","DOI":"10.4161\/fly.19695","volume":"6","author":"P Cingolani","year":"2012","unstructured":"Cingolani, P. et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly 6, 80\u201392 (2012).","journal-title":"Fly"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-31199-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-31199-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-31199-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T17:48:10Z","timestamp":1669312090000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-31199-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,24]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["31199"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-31199-2","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,24]]},"assertion":[{"value":"19 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"John Hilton\u2014Consulting: Merck, AZ, Novartis, Pfizer, Lilly, BMS; Research Funds: GSK, Lilly; DMC Committees: BMS. Karen Gelmon\u2014Consulting\/Advisory: AstraZeneca, Pfizer, Novartis, Lilly, Mylan, Merck, Gilead, Roche, Ayala, Nanostring, Genomic Health. Expert Testimony: Genentech. Research Funding: AstraZeneca, Pfizer, BMS, Roche. Philippe L. Bedard\u2014Dr. Bedard reports grants from BristolMyersSquibb, Sanofi, Genentech\/Roche, Novartis, GlaxoSmithKline, Nektar Therapeutics, Merck, Lilly, Servier, PTC Therapeutics, SeaGen, Mersana, Amgen, Zymeworks, VelosBio outside the submitted work; and Uncompensated advisory boards for BristolMyersSquibb, Sanofi, Pfizer, Genentech\/Roche, Amgen, Lilly, SeaGen, Merck. Anna Tinker\u2014Honoraria: AstraZeneca and Eisai; Grant\/research funding: AZ. Rachel Goodwin\u2014Speaker and Consultant: Merck, Pfizer, Bayer, Ipsen, Novartis (AAA), Eaisi, Amgen, Apobiologix. Research grant: Apobiologix, Ipsen, Novartis. Aaron R. Hansen\u2014Consulting or Advisory Role: Merck, GlaxoSmithKline, Bristol Myers Squibb, Eisai. Research Funding: Karyopharm Therapeutics, Merck, Bristol Myers Squibb, Boehringer IIngelheim, GlaxoSmithKline, Roche\/Genentech, Janssen, AstraZeneca\/Medimmune, Astellas Pharma, Macrogenics. Zachary W. Veitch\u2014has received honoraria from Pfizer and Genomic Health. Daniel J Renouf\u2014Research funding and honoraria from Bayer and Roche, and travel funding and honoraria from Servier, Celgene, Taiho, Ipsen, and AstraZeneca. John Soong\u2014Stockholder: Senhwa Biosciences. Kathleen Pritchard\u2014Honoraria\/Consulting: Pfizer, Roche, Amgen, Novartis, Eisai, Genomic Health Inc., Myriad Genetic Laboratories. Royalties: UpToDate. Lesley Seymour\u2014Research support to CCTG from Senhwa Biosciences for the current work. Samuel Aparicio\u2014SAp is a cofounder of Canexia Health Inc, Inflex Ltd, and scientific advisor to Sangamo Pharmaceuticals, Repare Pharmaceuticals. Funding: SAp is supported by Canada Research Chairs Program, Canada Foundation for Innovation. Work supported by StandUptoCancer, BC Cancer Foundation, Canadian Cancer Research Society, Canada Institutes for Health Research. David Cescon\u2014Consulting\/Advisory: AstraZeneca, Eisai, Exact Sciences, Gilead, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. Research funding to institutions: AstraZeneca, Gilead, GlaxoSmithKline, Inivata, Merck, Pfizer, and Roche. Patent (US62\/675,228) for methods of treating cancers characterized by a high expression level of spindle and kinetochore associated complex subunit 3 (ska3) gene. All other authors declare no potential conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3607"}}